Cytena Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 30
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $33.8M
Latest Deal Amount

Cytena General Information

Description

Developer of a single-cell printing technology designed to assist contact-free deposition of single cells encapsulated in micro-droplets. The company's technology is based on an inkjet-like print head with integrated imaging sensors, providing efficient and fast single-cell seeding combined with good cell viability and zero risk of cross contamination, enabling clients to deliver enhanced and efficient medication to their patients thereby improving their outcomes.

Contact Information

Website
www.cytena.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • Neuer Messplatz 3
  • 79108 Freiburg
  • Germany
+49 0761 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytena Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 05-Aug-2019 $33.8M 00.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 26-Mar-2019 00.00 00.00 000.00 Completed Generating Revenue
2. Grant 29-Nov-2017 $58.7K $1.2M Completed Startup
1. Seed Round 08-May-2015 $1.2M $1.2M 00.000 Completed Startup
To view Cytena’s complete valuation and funding history, request access »

Cytena Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a single-cell printing technology designed to assist contact-free deposition of single cells encapsulated i
Biotechnology
Freiburg, Germany
30 As of 2019
00.00
00.00 0000-00-00
000000&0 00.00

0000000

u fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia d
0000000000000
Lebanon, NH
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit e
0000000000000
Cambridge, MA
00 As of 0000
0000
0000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cytena Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avitide Venture Capital-Backed Lebanon, NH 00 000.00 000000&0 000.00
000000 Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
000000 00000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
0000000 Formerly VC-backed San Diego, CA 000 00000 000000&0 00000
000000 Formerly VC-backed Providence, RI 00 0000 000000000 - 0000
You’re viewing 5 of 15 competitors. Get the full list »

Cytena Executive Team (6)

Name Title Board Seat Contact Info
Jonas Schoendube Chief Executive Officer
Benjamin Steimle Chief Financial Officer
Andre Gross Chief Technology Officer
Fabian Stumpf Ph.D Chief Marketing Officer
Julian Riba Chief Scientific Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Cytena Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytena Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Germany's Federal Ministry of Economics and Technology Government 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
To view Cytena’s complete investors history, request access »